ReviewFrontiers in microbiology2026
Redox biology underlying the efficacy and toxicity of colistin as a last-resort antibiotic.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing prevalence of multidrug-resistant Gram-negative bacteria has reinforced the clinical importance of last-resort antibiotics such as colistin. Their antibacterial efficacy has made them indispensable for treating life-threatening infections, yet their clinical use is constrained by substantial toxicity. Increasing evidence indicates that redox biology may influence both the antibacterial activity and host toxicity of colistin through distinct biological processes. Reactive oxygen species contribute to bacterial killing while simultaneously promoting mitochondrial dysfunction, oxidative stress, inflammation, and tubular cell death within the kidney. This mini review summarizes current knowledge on the redox mechanisms underlying the antibacterial activity and host toxicity of last-resort antibiotics, with particular emphasis on colistin-induced nephrotoxicity. We discuss experimental and clinical evidence supporting host-directed redox modulation as a strategy to mitigate renal injury, highlighting the limitations that have hindered successful clinical translation. Finally, we examine emerging opportunities, including biomarker-guided strategies and mitochondria-targeted interventions, that may facilitate the development of safer therapeutic approaches while preserving the antibacterial efficacy of colistin.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.